[Treatment of hypertension with a fixed calcium antagonist-diuretic combination. Observations from treatment of 5,595 patients].
METHODS
In an observational study lasting 6 months, 5,595 patients with essential hypertension were treated with a combination of a calcium antagonist and a diuretic, with the aim of testing the efficacy and safety of the drug. Some 63.8% oft the patients had already received anti-hypertensive treatment; 67.3% of the patients also had accompanying diseases. Treatment was begun with a single daily tablet comprising 160 mg verapamil, 50 mg triamterene and 25 mg hydrochlorothiazide (Veratide), and the dose could be reduced to one-half or increased to two daily as indicted by the response of the blood pressure.


RESULTS
At the end of 6 months of treatment, the overall groups showed a decrease in both systolic and diastolic blood pressure of 15.2% (26/15 mmHg). Breakdown oft the patients into various age groups revealed no differences in the results. Responder rates varied between 62.0 and 71.8%. Among patients with isolated systolic hypertension, the response rate was 66.4%. In this form of hypertension only the systolic blood pressure was lowered. During the course of treatment, 6.8% of the patients developed side effects, which were severe in 0.9% of the cases. In only 143 of the 5,595 patients did the treatment have to be broken off.


CONCLUSIONS
The efficacy and safety oft the combination preparation investigated have been confirmed under doctor's office conditions. The decrease in diastolic blood pressure was more marked among smokers than among non-smokers.
Klaus
D
D
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006852:Hydrochlorothiazide / Q000009:adverse effects / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D014223:Triamterene / Q000009:adverse effects / Q000627:therapeutic use*; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; D006852:Hydrochlorothiazide; D014700:Verapamil; D014223:Triamterene
Hypertoniebehandlung mit einer fixen Kalziumantagonisten-Diuretikum-Kombination. Eine Anwendungsbeobachtung bei 5,595 Patienten.